Sign In
Buy UBX
$0.200
+0 (+0%)
At Close: Oct 10, 2025
UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference
04:03pm, Monday, 16'th Aug 2021
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of agi
UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates
04:01pm, Tuesday, 10'th Aug 2021
UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet ag
SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B
A Look At Unity's UBX1325 Phase 1 Results
04:11pm, Monday, 26'th Jul 2021
I recently covered Unity's transition away from its failed osteoarthritis program to its ophthalmology program focused on retinal diseases.
UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325
Takeaways On Unity Biotech's Clinical Data From A Bull Analyst
05:12pm, Tuesday, 06'th Jul 2021
Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ:UBX).
UBX1325's selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
04:01pm, Tuesday, 23'rd Mar 2021
SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of ag
UNITY Biotechnology Reports Granting of New Employment Inducement Award
04:05pm, Thursday, 11'th Mar 2021
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases
UNITY Biotechnology to Participate in Upcoming March Investor Conferences
04:05pm, Friday, 26'th Feb 2021
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
11:17am, Tuesday, 12'th Jan 2021
Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.
Unity Biotech, Aurinia Among Pharma Companies With R&D Flops in 2020
04:45pm, Friday, 18'th Dec 2020
Big names like Glaxo, Pfizer and Johnson & Johnson also abandoned promising programs
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY's Board
A Look Inside Unity Bio's Transition To An Ophthalmology Company
04:04pm, Friday, 27'th Nov 2020
Unity Bio was previously advancing a lead candidate aimed at reducing osteoarthritis pain by selectively clearing senescent cells in the knee. This candidate, UBX0101, was dropped by the company on Au
